Last reviewed · How we verify
Sestamibi
At a glance
| Generic name | Sestamibi |
|---|---|
| Also known as | Cardiolite |
| Sponsor | Lantheus Medical Imaging |
| Drug class | Radioactive Diagnostic Agent [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Myocardial Imaging
- Breast Imaging
Common side effects
- Taste Perversion
- Cardiovascular Events
- Chest Pain/Angina
- ST Segment Changes
- Breast Pain
- Headache
- Parosmia
Serious adverse events
- Seizure
- Severe Hypersensitivity (dyspnea, hypotension, bradycardia, asthenia, vomiting)
- Angioedema
- Arrhythmia
- Syncope
- Transient Arthritis
- Death
Drug interactions
- None specified
Key clinical trials
- Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma (PHASE1)
- SPECT/CT for the Characterization of Renal Masses
- Tc99m Sestamibi Molecular Breast Imaging (NA)
- Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR) (PHASE3)
- Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue (NA)
- Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer (NA)
- DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer (EARLY_PHASE1)
- Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |